Report cover image

The Worldwide Market for Liquid Biopsy, 6th Edition

Publisher Kalorama Information
Published Dec 01, 2023
SKU # KLI18399945

Description

The Worldwide Market for Liquid Biopsy, 6th Edition


Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods.

Key applications of liquid biopsy testing in clinical oncology include:

1. Early Detection and Diagnosis/Screening:

Identifying cancer at an early stage.

2. Alternative Testing Method:

When tissue biopsy is challenging or impossible.
When the primary site of metastatic disease is unknown.

3. Therapy Personalization and Monitoring:

Molecular characterization to select optimal therapy.
Monitoring treatment efficacy and adjusting therapy in case of resistance.

4. Disease Monitoring:

Observing disease progression, tumor evolution, residual disease.
Early detection of recurrence.

5. Prognosis of Disease:

Assessing the likely course and outcome of the disease.

The liquid biopsy market is experiencing significant changes, and The Worldwide Market for Liquid Biopsy, 6th Edition from Kalorama Information provides an in-depth assessment of the market opportunity from 2023 to 2028. It covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types.

Key Market Segments:

By Region:
North America
Europe
Asia
Rest of World

By Type of Liquid Biopsy:

CTC-based Liquid Biopsy
ctDNA-based Liquid Biopsy
EV and Exosome-based Liquid Biopsy
Multi-Analyte-based Liquid Biopsy
Other Analytes Liquid Biopsy

By Type of Cancer:

Breast
Lung
Colorectal
Ovarian
Prostate
Pan-Cancer
Other Cancers
R&D and Selected Tests:
Selected ctDNA-based Liquid Biopsy Tests in Development
Selected CTC-based Liquid Biopsy Tests in 2023
Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023

The growing acceptance of liquid biopsy, even during the COVID-19 pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy's potential in combination with other technologies further contributes to its expanding applications and market growth.

The report also profiles key companies in the liquid biopsy market. These include:

Adaptive Biotechnologies
Agena Bioscience, Inc.
Angle, PLC
Aspira Women’s Health
Biocartis Group Nv
Biocept, Inc. (closed)
Biodesix
Cellmax Life
Circulogene
Diacarta, Inc.
Epic Sciences
Epigenomics AG (closed)
Exact Sciences
Exosome Diagnostics, Inc.
Foundation Medicine, Inc. (Roche)
Freenome, Inc.
Gilupi Gmbh
Grail (Illumina)
Guardant Health, Inc.
Hologic
Lunglife AI (Formerly Cynvenio Biosystems)
Menarini-Silicon Biosystems, SPA
Myriad Genetics, Inc.
Natera, Inc.
Neogenomics Laboratories, Inc.
Oncocyte Corporation
Oncodna S.A.
Personal Genome Diagnostics
Qiagen N.V.
Cell-Free DNA Technologies
Ctc Technologies
Exosome And Mirna Technologies
Resolution Biosciences (Agilent)
Roche Diagnostics
Sysmex-Inostics, Inc.
Tempus
Volitionrx

Table of Contents

    • Introduction
    • Liquid Biopsy Technologies
    • Industry Structure
    • Liquid Biopsy Market Revenues and Forecast
    • Introduction
    • Current Major Liquid Biopsy Technologies
    • Introduction
    • Advantages and Limitations of ctDNA in Liquid Biopsy
    • Current ctDNA-based Liquid Biopsy Tests
    • ctDNA-based Liquid Biopsy Tests in Development
    • Introduction
    • Challenges in the Development of CTC-based Liquid Biopsy Tests
    • CTC-based Liquid Biopsy Tests
    • Selected CTC-based Liquid Biopsy Tests in Development
    • Introduction
    • Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
    • Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
    • Introduction
    • Liquid Biopsy Tests Based on Multiple Analytes
    • Multiple Analyte-based Liquid Biopsy Tests in Development
    • Introduction
    • Liquid Biopsy Tests for Research Use Only
    • Introduction
    • Tiers of Competition
    • Competitive Factors
    • Significant Market Trends
    • Competitors No Longer in the Liquid Biopsy Market
    • Market Overview
    • Market Forecast
    • Circulating Tumor DNA
    • Circulating Tumor Cells
    • Extracellular Vesicles and Other Analytes
    • Multiple Analytes
    • Therapy Guidance and Monitoring
    • Diagnosis/Screening
    • Disease Prognosis
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Other Cancers
    • Pan-Cancer Tests
    • Companies in the Market
    • Adaptive Biotechnologies
    • Agena Bioscience, Inc.
    • ANGLE, plc
    • Aspira Women’s Health
    • Biocartis Group NV
    • Biocept, Inc. (closed)
    • Biodesix
    • CellMax Life
    • Circulogene
    • DiaCarta, Inc.
    • Epic Sciences
    • Epigenomics AG (closed)
    • Exact Sciences
    • Exosome Diagnostics, Inc.
    • Foundation Medicine, Inc. (Roche)
    • Freenome, Inc.
    • GILUPI GmbH
    • GRAIL (Illumina)
    • Guardant Health, Inc.
    • Hologic
    • LungLife AI (formerly Cynvenio Biosystems)
    • Menarini-Silicon Biosystems, Spa
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • NeoGenomics Laboratories, Inc.
    • Oncocyte Corporation
    • OncoDNA S.A.
    • Personal Genome Diagnostics
    • QIAGEN N.V.
    • Resolution Biosciences (Agilent)
    • Roche Diagnostics
    • Sysmex-Inostics, Inc.
    • Tempus
    • VolitionRx

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us